Thymocyte-specific truncation of the deubiquitinating domain of CYLD impairs positive selection in a NF-κB essential modulator-dependent manner

Journal of Immunology

Volumn 185, Issue 4, 2010, Pages 2032-2043

  Tsagaratou, Ageliki ^a,b   Trompouki, Eirini ^b,c   Grammenoudi, Sofia ^b   Kontoyiannis, Dimitris L ^b   Mosialos, George ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE; CYLD PROTEIN, MOUSE; CYSTEINE PROTEINASE; LYMPHOCYTE ANTIGEN RECEPTOR; NEMO PROTEIN, MOUSE; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYLINDROMA; FEMALE; GENE DELETION; GENE MUTATION; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE; THYMOCYTE; TRANSGENE; TUMOR SUPPRESSOR GENE; UBIQUITINATION; ANIMAL; BINDING SITE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOLOGY; FLOW CYTOMETRY; GENETICS; IMMUNOBLOTTING; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; MOUSE STRAIN; MUTATION; THYMUS; TRANSGENIC MOUSE;

ANIMALS; BINDING SITES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYSTEINE ENDOPEPTIDASES; FEMALE; FLOW CYTOMETRY; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; NF-KAPPA B; RECEPTORS, ANTIGEN, T-CELL; THYMUS GLAND; UBIQUITINATION;

EID: 77956914055     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903919     Document Type: Article

References (44)

1. Borodovsky, A., H. Ovaa, N. Kolli, T. Gan-Erdene, K. D. Wilkinson, H. L. Ploegh, and B. M. Kessler. 2002. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9: 1149-1159.
2. Trompouki, E., E. Hatzivassiliou, T. Tsichritzis, H. Farmer, A. Ashworth, and G. Mosialos. 2003. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424: 793-796.
3. Kovalenko, A., C. Chable-Bessia, G. Cantarella, A. Israël, D. Wallach, and G. Courtois. 2003. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424: 801-805.
4. Bignell, G. R., W. Warren, S. Seal, M. Takahashi, E. Rapley, R. Barfoot, H. Green, C. Brown, P. J. Biggs, S. R. Lakhani, et al. 2000. Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 25: 160-165.
5. Hellerbrand, C., E. Bumes, F. Bataille, W. Dietmaier, R. Massoumi, and A. K. Bosserhoff. 2007. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28: 21-27.
6. Zhong, S., C. R. Fields, N. Su, Y. X. Pan, and K. D. Robertson. 2007. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26: 2621-2634.
7. Keats, J. J., R. Fonseca, M. Chesi, R. Schop, A. Baker, W. J. Chng, S. Van Wier, R. Tiedemann, C. X. Shi, M. Sebag, et al. 2007. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144.
8. Annunziata, C. M., R. E. Davis, Y. Demchenko, W. Bellamy, A. Gabrea, F. Zhan, G. Lenz, I. Hanamura, G. Wright, W. Xiao, et al. 2007. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130.
9. Jenner, M. W., P. E. Leone, B. A. Walker, F. M. Ross, D. C. Johnson, D. Gonzalez, L. Chiecchio, E. Dachs Cabanas, G. P. Dagrada, M. Nightingale, et al. 2007. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110: 3291-3300.
10. Courtois, G. 2008. Tumor suppressor CYLD: negative regulation of NF-kappaB signaling and more. Cell. Mol. Life Sci. 65: 1123-1132.
11. Sun, S. C. 2009. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 17: 25-34.
12. Massoumi, R. 2010. Ubiquitin chain cleavage: CYLD at work. Trends Biochem. Sci. DOI:10.1016/j.tibs.2010.02.007.
13. Costello, C. M., N. Mah, R. Häsler, P. Rosenstiel, G. H. Waetzig, A. Hahn, T. Lu, Y. Gurbuz, S. Nikolaus, M. Albrecht, et al. 2005. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med. 2: e199.
14. Reiley, W. W., W. Jin, A. J. Lee, A. Wright, X. Wu, E. F. Tewalt, T. O. Leonard, C. C. Norbury, L. Fitzpatrick, M. Zhang, and S. C. Sun. 2007. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J. Exp. Med. 204: 1475-1485.
15. Reiley, W. W., M. Zhang, W. Jin, M. Losiewicz, K. B. Donohue, C. C. Norbury, and S. C. Sun. 2006. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat. Immunol. 7: 411-417.
16. Zhang, J., B. Stirling, S. T. Temmerman, C. A. Ma, I. J. Fuss, J. M. Derry, and A. Jain. 2006. Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J. Clin. Invest. 116: 3042-3049.
17. Jin, W., W. R. Reiley, A. J. Lee, A. Wright, X. Wu, M. Zhang, and S. C. Sun. 2007. Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells. J. Biol. Chem. 282: 15884-15893.
18. Hövelmeyer, N., F. T. Wunderlich, R. Massoumi, C. G. Jakobsen, J. Song, M. A. Wörns, C. Merkwirth, A. Kovalenko, M. Aumailley, D. Strand, et al. 2007. Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD. J. Exp. Med. 204: 2615-2627.
19. Trompouki, E., A. Tsagaratou, S. K. Kosmidis, P. Dollé, J. Qian, D. L. Kontoyiannis, W. V. Cardoso, and G. Mosialos. 2009. Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia 11: 469-476.
20. Orban, P. C., D. Chui, and J. D. Marth. 1992. Tissue- and site-specific DNA recombination in transgenic mice. Proc. Natl. Acad. Sci. USA 89: 6861-6865.
21. Schmidt-Supprian, M., W. Bloch, G. Courtois, K. Addicks, A. Israël, K. Rajewsky, and M. Pasparakis. 2000. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol. Cell 5: 981-992.
22. Reiley, W., M. Zhang, and S. C. Sun. 2004. Negative regulation of JNK signaling by the tumor suppressor CYLD. J. Biol. Chem. 279: 55161-55167.
23. Tanchot, C., A. Le Campion, B. Martin, S. Léaument, N. Dautigny, and B. Lucas. 2002. Conversion of naive T cells to a memory-like phenotype in lymphopenic hosts is not related to a homeostatic mechanism that fills the peripheral naive T cell pool. J. Immunol. 168: 5042-5046.
24. Voehringer, D., H. E. Liang, and R. M. Locksley. 2008. Homeostasis and effector function of lymphopenia-induced "memory-like" T cells in constitutively T cell-depleted mice. J. Immunol. 180: 4742-4753.
25. Bendelac, A., P. Matzinger, R. A. Seder, W. E. Paul, and R. H. Schwartz. 1992. Activation events during thymic selection. J. Exp. Med. 175: 731-742.
26. Azzam, H. S., A. Grinberg, K. Lui, H. Shen, E. W. Shores, and P. E. Love. 1998. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J. Exp. Med. 188: 2301-2311.
27. Aliahmad, P., and J. Kaye. 2008. Development of all CD4 T lineages requires nuclear factor TOX. J. Exp. Med. 205: 245-256.
28. Albu, D. I., D. Feng, D. Bhattacharya, N. A. Jenkins, N. G. Copeland, P. Liu, and D. Avram. 2007. BCL11B is required for positive selection and survival of double-positive thymocytes. J. Exp. Med. 204: 3003-3015.
29. Hettmann, T., J. DiDonato, M. Karin, and J. M. Leiden. 1999. An essential role for nuclear factor kappaB in promoting double positive thymocyte apoptosis. J. Exp. Med. 189: 145-158.
30. Ma, A., J. C. Pena, B. Chang, E. Margosian, L. Davidson, F. W. Alt, and C. B. Thompson. 1995. Bclx regulates the survival of double-positive thymocytes. Proc. Natl. Acad. Sci. USA 92: 4763-4767.
31. Teh, H. S., P. Kisielow, B. Scott, H. Kishi, Y. Uematsu, H. Blüthmann, and H. von Boehmer. 1988. Thymic major histocompatibility complex antigens and the alpha beta T-cell receptor determine the CD4/CD8 phenotype of T cells. Nature 335: 229-233.
32. Barnden, M. J., J. Allison, W. R. Heath, and F. R. Carbone. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76: 34-40.
33. Jimi, E., I. Strickland, R. E. Voll, M. Long, and S. Ghosh. 2008. Differential role of the transcription factor NF-kappaB in selection and survival of CD4+ and CD8+ thymocytes. Immunity 29: 523-537.
34. Matsuzawa, A., P. H. Tseng, S. Vallabhapurapu, J. L. Luo, W. Zhang, H. Wang, D. A. Vignali, E. Gallagher, and M. Karin. 2008. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science 321: 663-668.
35. Yamamoto, M., T. Okamoto, K. Takeda, S. Sato, H. Sanjo, S. Uematsu, T. Saitoh, N. Yamamoto, H. Sakurai, K. J. Ishii, et al. 2006. Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat. Immunol. 7: 962-970.
36. Schmidt-Supprian, M., G. Courtois, J. Tian, A. J. Coyle, A. Israël, K. Rajewsky, and M. Pasparakis. 2003. Mature T cells depend on signaling through the IKK complex. Immunity 19: 377-389.
37. Skaug, B., X. Jiang, and Z. J. Chen. 2009. The role of ubiquitin in NF-kappaB regulatory pathways. Annu. Rev. Biochem. 78: 769-796.
38. Iwai, K., and F. Tokunaga. 2009. Linear polyubiquitination: a new regulator of NF-kappaB activation. EMBO Rep. 10: 706-713.
39. Xia, Z. P., L. Sun, X. Chen, G. Pineda, X. Jiang, A. Adhikari, W. Zeng, and Z. J. Chen. 2009. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 461: 114-119.
40. Schmidt-Supprian, M., J. Tian, H. Ji, C. Terhorst, A. K. Bhan, E. P. Grant, M. Pasparakis, S. Casola, A. J. Coyle, and K. Rajewsky. 2004. I kappa B kinase 2 deficiency in T cells leads to defects in priming, B cell help, germinal center reactions, and homeostatic expansion. J. Immunol. 173: 1612-1619.
41. Sato, T., S. Ohno, T. Hayashi, C. Sato, K. Kohu, M. Satake, and S. Habu. 2005. Dual functions of Runx proteins for reactivating CD8 and silencing CD4 at the commitment process into CD8 thymocytes. Immunity 22: 317-328.
42. Taniuchi, I., M. Osato, T. Egawa, M. J. Sunshine, S. C. Bae, T. Komori, Y. Ito, and D. R. Littman. 2002. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 111: 621-633.
43. Egawa, T., and D. R. Littman. 2008. ThPOK acts late in specification of the helper T cell lineage and suppresses Runx-mediated commitment to the cytotoxic T cell lineage. Nat. Immunol. 9: 1131-1139.
44. Rincón, M., A. Whitmarsh, D. D. Yang, L. Weiss, B. Dérijard, P. Jayaraj, R. J. Davis, and R. A. Flavell. 1998. The JNK pathway regulates the In vivo deletion of immature CD4(+)CD8(+) thymocytes. J. Exp. Med. 188: 1817-1830.